Status and phase
Conditions
Treatments
About
The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible subjects will be randomly assigned (by chance) to receive BEM or matching placebo orally for 5 days. Co-administration of locally available standard of care (SOC) is allowed. The total duration of the study is 60 days.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Positive SARS-CoV-2 test conducted ≤ 5 days prior to randomization
Mild or moderate COVID-19 with symptom onset ≤ 5 days before randomization and at least one COVID-19 related symptom present at time of screening
Subject must be high risk, defined below:
Use of adequate contraception for females of childbearing potential
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
2,295 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Clinical Trials Administrator
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal